Cedar Pollen Allergy - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Cedar Pollen Allergy - Pipeline Review, H2 2018’, provides an overview of the Cedar Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cedar Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy

- The report reviews pipeline therapeutics for Cedar Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Cedar Pollen Allergy therapeutics and enlists all their major and minor projects

- The report assesses Cedar Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Cedar Pollen Allergy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cedar Pollen Allergy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Astellas Pharma Inc

F. Hoffmann-La Roche Ltd

REGiMMUNE Corp

Stallergenes Greer plc

Astellas Pharma Inc

F. Hoffmann-La Roche Ltd

REGiMMUNE Corp

Stallergenes Greer plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cedar Pollen Allergy – Overview

Cedar Pollen Allergy – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cedar Pollen Allergy – Overview

Cedar Pollen Allergy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cedar Pollen Allergy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cedar Pollen Allergy – Companies Involved in Therapeutics Development

Astellas Pharma Inc

F. Hoffmann-La Roche Ltd

REGiMMUNE Corp

Stallergenes Greer plc

Cedar Pollen Allergy – Drug Profiles

ASP-4070 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Cedar Pollen Allergy – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGI-1001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STG-120 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cedar Pollen Allergy – Dormant Projects

Cedar Pollen Allergy – Discontinued Products

Cedar Pollen Allergy – Product Development Milestones

Featured News & Press Releases

Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference

Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting

Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy

Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Cedar Pollen Allergy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Tables

Number of Products under Development for Cedar Pollen Allergy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Cedar Pollen Allergy – Pipeline by Astellas Pharma Inc, H2 2018

Cedar Pollen Allergy – Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Cedar Pollen Allergy – Pipeline by REGiMMUNE Corp, H2 2018

Cedar Pollen Allergy – Pipeline by Stallergenes Greer plc, H2 2018

Cedar Pollen Allergy – Dormant Projects, H2 2018

Cedar Pollen Allergy – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Cedar Pollen Allergy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Figures

Number of Products under Development for Cedar Pollen Allergy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports